
    
      This is an expanded access study with a total of 300 participants with NET and suspected SSTR
      positive tumors. Eligible participants will undergo baseline assessments at enrollment. Study
      participants will receive 68Ga-DOTATATE and will undergo a PET/CT imaging study. All patients
      referred by Oncologists will be screened by a UCLA Nuclear Medicine physician and then
      accepted for scanning if clinically appropriate.
    
  